Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 2676254, 6 pages
https://doi.org/10.1155/2017/2676254
Case Report

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review

1University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195, USA
2Department of Laboratory Medicine, University of Washington School of Medicine, P.O. Box 357110, 1959 NE Pacific Street, Seattle, WA 98195, USA
3Department of Medicine, University of Washington School of Medicine, P.O. Box 356420, 1959 NE Pacific Street, Seattle, WA 98195, USA
4Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA

Correspondence should be addressed to Ryan D. Cassaday; ude.wu@yadassac

Received 8 November 2016; Revised 9 January 2017; Accepted 31 January 2017; Published 21 February 2017

Academic Editor: Tatsuharu Ohno

Copyright © 2017 D. Alan Potts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Coiffier, E. Lepage, J. Brière et al., “CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma,” New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. T. M. Habermann, E. A. Weller, V. A. Morrison et al., “Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3121–3127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, “A predictive model for aggressive non-Hodgkin's lymphoma,” New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993. View at Publisher · View at Google Scholar
  4. N. A. Johnson, K. J. Savage, O. Ludkovski et al., “Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival,” Blood, vol. 114, no. 11, pp. 2273–2279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. J. Savage, N. A. Johnson, S. Ben-Neriah et al., “MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy,” Blood, vol. 114, no. 17, pp. 3533–3537, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Copie-Bergman, P. Cuillière-Dartigues, M. Baia et al., “MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study,” Blood, vol. 126, no. 22, pp. 2466–2474, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. N. A. Johnson, G. W. Slack, K. J. Savage et al., “Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3452–3459, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Jessy, “Immunity over inability: the spontaneous regression of cancer,” Journal of Natural Science, Biology and Medicine, vol. 2, no. 1, pp. 43–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. Horning and S. A. Rosenberg, “The natural history of initially untreated low-grade non-Hodgkin's lymphomas,” The New England Journal of Medicine, vol. 311, no. 23, pp. 1471–1475, 1984. View at Publisher · View at Google Scholar · View at Scopus
  10. S. H. Swerdlow, E. Campo, S. A. Pileri et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, vol. 127, no. 20, pp. 2375–2390, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. B. D. Cheson, R. I. Fisher, S. F. Barrington et al., “Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification,” Journal of Clinical Oncology, vol. 32, no. 27, pp. 3059–3067, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. H. H. Gattiker, E. Wiltshaw, and D. A. G. Galton, “Spontaneous regression in non-Hodgkin's lymphoma,” Cancer, vol. 45, no. 10, pp. 2627–2632, 1980. View at Publisher · View at Google Scholar · View at Scopus
  13. J. G. Krikorian, C. S. Portlock, D. P. Cooney, and S. A. Rosenberg, “Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases,” Cancer, vol. 46, no. 9, pp. 2093–2099, 1980. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Valera, A. López-Guillermo, T. Cardesa-Salzmann et al., “MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy,” Haematologica, vol. 98, no. 10, pp. 1554–1562, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Wang, S. Hu, X. Lu, K. H. Young, and L. J. Medeiros, “Triple-hit B-cell Lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: clinicopathologic features of 11 cases,” American Journal of Surgical Pathology, vol. 39, no. 8, pp. 1132–1139, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. M. Green, K. H. Young, C. Visco et al., “Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3460–3467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Takahashi, K. Miura, M. Nakagawa et al., “Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy,” Leukemia and Lymphoma, vol. 57, no. 12, pp. 2784–2790, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. A. M. Perry, D. Crockett, B. J. Dave et al., “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases,” British Journal of Haematology, vol. 162, no. 1, pp. 40–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. L. Grem, G. R. Hafez, J. H. Brandenburg, and P. P. Carbone, “Spontaneous remission in diffuse large cell lymphoma,” Cancer, vol. 57, no. 10, pp. 2042–2044, 1986. View at Publisher · View at Google Scholar · View at Scopus
  21. M. G. McCabe, C. E. Hook, and G. A. A. Burke, “Spontaneous regression of an EBV-associated monoclonal large B cell proliferation in the mastoid of a young child following surgical biopsy,” Pediatric Blood and Cancer, vol. 51, no. 4, pp. 557–559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Abe, K. Ogawa, Y. Maruyama, N. Nakamura, and M. Abe, “Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus: a case report and review of the literature,” Journal of Clinical and Experimental Hematopathology, vol. 47, no. 1, pp. 23–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B. Karnad, A. Jaffar, and R. H. Lands, “Spontaneous regression of acquired immune deficiency syndrome-related, high-grade, extranodal non-Hodgkin's lymphoma,” Cancer, vol. 69, no. 7, pp. 1856–1857, 1992. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kumamoto, H. Nakamine, T. Hara et al., “Spontaneous complete regression of high grade non‐Hodgkin's lymphoma. Morphologic, immunohistochemical, and gene amplification analyses,” Cancer, vol. 74, no. 11, pp. 3023–3028, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. R. D. Cassaday, J. T. Malik, and J. E. Chang, “Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature,” Clinical Lymphoma, Myeloma and Leukemia, vol. 11, no. 3, pp. 289–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Goodman, S. P. Patel, and R. Kurzrock, “PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas,” Nature Reviews Clinical Oncology, 2016. View at Publisher · View at Google Scholar
  27. P. Armand, “Immune checkpoint blockade in hematologic malignancies,” Blood, vol. 125, no. 22, pp. 3393–3400, 2015. View at Publisher · View at Google Scholar · View at Scopus